1. MARKETS
  2. SECTOR : BANKING & FINANCE
  3. INDUSTRY : FINANCIAL CONGLOMERATES
  4. BRIDGEBIO ONCOLOGY THERAPEUTICS INC.
BridgeBio Oncology Therapeutics Inc.
XNAS: BBOT
Download real time
3.60-0.29(-7.46%)
New 52W Low today
481.6K
XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

BridgeBio Oncology Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

BridgeBio Oncology Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue BridgeBio Oncology Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit BridgeBio Oncology Therapeutics Inc Jun-2026 Quarterly Net Profit is $-56 Million which is growth of -98.5% YoY.

BridgeBio Oncology Therapeutics Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24
Operating Rev.
Cost Of Rev.
----------
Gross Profit
----------
⌄
60.246.243.449.230.123.121.919.723.915.5
Operating Profit
-60.2-46.2-43.4-49.2-30.1-23.1-21.9-19.7-23.9-15.5
⌄
3.63.94.43.41.71.82.12.51.80
Profit Before Tax
-56.5-42.1-38.8-44.8-28.4-22.1-19.7-17.3-21.8-15.4
Tax
----------
⌄
-56.5-42.1-38.8-44.8-28.4-22.1-19.7-17.3-21.8-15.4
Diluted NI Avail to Com Stockholders Ann.
-56.5-42.1-38.8-44.8-28.4-22.1-19.7-17.3-21.8-15.4
Basic EPS
-0.7-0.5-0.5-1-0.4-0.3-0.3-0.2-0.3-0.2
Diluted EPS After ExtraOrdinary
-0.7-0.5-0.5-1-0.4-0.3-0.3-0.2-0.3-0.2
Number Of Shares End
80.1808043.579.279.279.279.279.279.2
Net Income Continuing Discontinued Operations
-56.5-42.1-38.8-44.8-28.4-22.1-19.7-17.3-21.8-15.4
Normalized Income
-56.5-42.1-38.8-44.8-28.4-22.1-19.7-17.3-21.8-15.4
Interest Income
3.63.94.43.41.71.82.12.51.80
Interest
----------
Net Interest Income
3.63.94.43.41.71.82.12.51.80
EBIT
-60.2-46.2-43.4-49.2-30.1-23.1-21.9-19.7-23.9-15.5
EBITDA
-60-46-43.2-49-29.9-23.1-21.8-19.6-23.8-15.4
Reconciled Cost Of Rev.
----------
Reconciled Depr.
0.20.20.20.20.20.10.10.10.10.1
Profit From Continuing Operations
-56.5-42.1-38.8-44.8-28.4-22.1-19.7-17.3-21.8-15.4
Normalized EBITDA
-60-46-43.2-49-29.9-23.1-21.8-19.6-23.8-15.4
*All financials are in USD Million and price data in USD
Add metric to table
Search...

BridgeBio Oncology Therapeutics Inc competitor comparison and performance snapshot within industry

BridgeBio Oncology Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue BridgeBio Oncology Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Annual Net Profit BridgeBio Oncology Therapeutics Inc Annual Net Profit is $-134 Million which is growth of -80.5% YoY.

BridgeBio Oncology Therapeutics Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphTTMDec '25Dec '24Dec '23
⌄
 
Cost Of Rev. Ann.
 ---
Gross Profit Ann.
 ---
Operating Exp. Ann.
199145.880.964.8
Operating Profit Ann.
-199-145.8-80.9-64.8
⌄
15.411.36.40.1
Other Exp. Ann.
 0.40.2-
PBT Ann.
-182.1-134-74.3-64.7
Tax Ann.
 ---
⌄
-182.1-134-74.3-64.7
Diluted NI Avail to Com Stockholders Ann.
-182.1-134-74.3-64.7
EPS Ann.
 -4.3-0.9-0.8
Diluted EPS Ann.
 -4.3-0.9-0.8
Number Of Shares End
 8079.2-
Total Exp. Ann.
 145.880.964.8
Net Income Continuing Discontinued Operations Ann.
-182.1-134-74.3-64.7
Normalized Income Ann.
-182.1-134-74.3-64.7
Interest Income Ann.
15.411.36.40.1
Interest Ann.
 ---
EBITDA Ann.
-198.2-145.2-80.7-64.7
Reconciled Cost Of Rev. Ann.
 ---
Reconciled Depr. Ann.
0.80.60.20.1
Profit From Continuing Operations Ann.
-182.1-134-74.3-64.7
Normalized EBITDA Ann.
-198.2-145.2-80.7-64.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
80.2%
2Y CAGR
50%

BridgeBio Oncology Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund BridgeBio Oncology Therapeutics Inc Dec-2025 Total Shareholders Fund is $411 Million which is growth of 330.1% YoY.

  • POSITIVE

    Total Assets BridgeBio Oncology Therapeutics Inc Dec-2025 Total Assets is $448 Million which is growth of 172.9% YoY.

BridgeBio Oncology Therapeutics Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphDec '25Dec '24Dec '23
⌄
448.4164.35.9
⌄
37.3342.9121.6
⌄
411.1-178.6-115.6
Total Capitalization Ann.
411.1-178.6-115.6
Tangible Assets Ann.
411.1-178.6-115.6
Working Capital Ann.
397.4139.1-12.8
Invested Capital Ann.
411.1-178.6-115.6
Tangible Book Value Ann.
411.1-178.6-115.6
Borrowings Ann.
2.8--
Net Debt Ann.
---
Share Issued Ann.
8079.279.2
Number Of Shares End
8079.2-
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
172.9%
2Y CAGR
771.8%
Total Current Liabilities Ann.
1Y CHG
78.6%
2Y CAGR
44.3%

BridgeBio Oncology Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share BridgeBio Oncology Therapeutics Inc Book Value Per Share is $4 which is growth of 240.2% YoY.

  • NEUTRAL

    ROE BridgeBio Oncology Therapeutics Inc ROE is 0% which is growth of 0% YoY.

BridgeBio Oncology Therapeutics Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphDec '25Dec '24Dec '23
RoA Ann. %
---
ROE Ann. %
---
ROIC %
---
OPM Ann. %
---
Inventory Turnover Ratio Ann.
---
Asset Turnover Ann. %
---
Working Capital Turnover Ann.
Quick Ratio Ann.
---
Current Ratio Ann.
---
Interest Coverage Ratio Ann.
---
LT Debt To Equity Ann.
---
*All financials are in USD Million and price data in USD
Add metric to table
Search...

BridgeBio Oncology Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity BridgeBio Oncology Therapeutics Inc Cash From Operating Activity is $-114 Million which is growth of -107.0% YoY.

  • POSITIVE

    Net Cash Flow BridgeBio Oncology Therapeutics Inc Net Cash Flow is $343 Million which is growth of 1015.5% YoY.

BridgeBio Oncology Therapeutics Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphDec '25Dec '24Dec '23
⌄
-113.9-55-52.1
⌄
73.3-120.5-2.8
⌄
383.4206.355.1
Cash Plus Cash Eqv. End Of Year Ann.
373.8310.3
Net Increase In Cash Plus Cash Eqv.s Ann.
342.830.70.2
Cash Plus Cash Eqv. Begin Of Year Ann.
310.30
Income Tax Paid Supplemental Data Ann.
---
Interest Paid Supplemental Data Ann.
---
Capex Ann.
-0.6-0.1-0.4
Issuance Of Capital Stock Ann.
22.2206.255.1
Issuance Of Debt Ann.
---
Repayment Of Debt Ann.
---
Repurchase Of Capital Stock Ann.
---
Free Cash Flow Ann.
-114.5-55.1-52.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
85.8%
2Y CAGR
163.8%
×